AstraZeneca Pharma India share news and announcements

NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap

Formerly Astra IDL

₹5,988.50₹112.50 (1.84%)BSE ₹5,988.15

Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.

52-week range of traded prices to 23 Oct 2026

₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025

Market cap: ₹14,971 Cr333rd largest listed
P/E: 88.3
P/B: 17.2
Dividend yield: 0.60%
ROE: 20.6%
ROCE: 24.4%
Debt to equity: 0.00
Volume, NSE: 7,11847.8% delivered

AstraZeneca Pharma India share news and announcements

671 announcements, routine notices left out, newest first. Page 10 of 14.

Jul 2017
- 28 Jul · Updates
  Company letter dated August 24, 2016 intimating the exchanges about the termination of distribution arrangement by AstraZeneca UK Limited for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc., of its late-stage small molecule antibiotics business. We also refer to our announcement dated December 1, 2016 intimating the exchanges about the validity period of the distribution agreement being extended upto July 31, 2017, due to delay in the divestment of AstraZeneca s global rights to Meronem and our further announcement dated January 19, 2017 intimating the exchanges about the transitional arrangements with Pfizer during the interim period. We now wish to further update that the Company has received a letter from AstraZeneca UK Limited to further extend the date of withdrawal of Meronem from July 31, 2017 to August 31, 2017, due to the delay in the divestment of AstraZeneca s global right to Meronem (opens in a new tab)
- 25 Jul · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. (opens in a new tab)
- 22 Jul · Updates
  Launch of Osimertinib Tablet 40 mg and 80 mg ( Tagrisso) in India. (opens in a new tab)
- 3 Jul · Legal
  Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 29-Jun-2017, regarding appointment of Mr. Gagan Singh Bedi as Additional Director on the Board.On basis of above you are required to clarify following -1. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is enclosed. (opens in a new tab)
Jun 2017
- 29 Jun · Legal
  Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 29-Jun-2017, regarding appointment of Mr. Gagan Singh Bedi as Additional Director on the Board.On basis of above you are required to clarify following -1. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
- 29 Jun · Change in Managing Director
  At the Board Meeting of the Company held on June 29, 2017, the Board considered and transacted inter alia the following business: 1. Pursuant to Mr. Sanjay Murdeshwar taking on a global role within the AstraZeneca group, based in Gaithersburg, Maryland, USA, he has offered to resign as Managing Director of the Company, ipso facto, as a Director of the Company with effect from the close of business hours on June 30, 2017. The Board has accepted his resignation. 2. The Board has co-opted Mr. Gagan Singh Bedi as Additional Director on the Board, who will take over as the Managing Director of the Company with effect from July 1, 2017. (opens in a new tab)
- 15 Jun · Updates
  AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC of Budesonide 320 g +Formoterol Fumarate Dihydrate 9 g inhalation powder. FDC of Budesonide 320 g + Formoterol Fumarate Dihydrate 9 g inhalation powder (Symbicort Turbuhaler 320/9 g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting β-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations. (opens in a new tab)
- 8 Jun · Results
  Resubmission of financial results for the quarter and year ended march 31, 2017. (opens in a new tab)
May 2017
- 31 May · Management
  Resignation of Mr Ian Brimicombe as Non- Executive Director of the company w.e.f. May 31, 2017. (opens in a new tab)
- 29 May · Updates
  AstraZeneca pharma India Limited receives import and market permission in form 45(Meeting Authorizarion) from Drug Controller general of India(DCGI) for Osimertinib tablet 40mg and 80mg. (opens in a new tab)
- 9 May · Results
  Financial results for the period ended March 31, 2017. (opens in a new tab)
Apr 2017
- 25 Apr · Board meeting
  Inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2017. Further that the 'Trading Window' shall remain closed for all Designated Persons, from March 16, 2017 to May 11, 2017 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. (opens in a new tab)
- 8 Apr · Disclosure
  Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. (opens in a new tab)
Feb 2017
- 24 Feb · Updates
  Company's Registrar and Share Transfer Agent- M/s Integrated Enterprises (India) Limited has informed the Company vide their letter dated February 20, 2017 that the Registry activity of M/s. Integrated Enterprises (India) Limited, is transferred to M/s. Integrated Registry Management Services Private Limited pursuant to the scheme of de-merger as approved by the High Court of Chennai. Henceforth, the Company's share transfer registry will be managed by M/s. Integrated Registry Management Services Private Limited. (opens in a new tab)
- 6 Feb · Legal
  Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 03-Feb-2017, regarding "AstraZeneca Pharma India Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on February 02, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is enclosed. (opens in a new tab)
- 3 Feb · Legal
  Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 03-Feb-2017, regarding "AstraZeneca Pharma India Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on February 02, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
- 3 Feb · Board meeting
  Outcome of meeting of the Board of Directors of the Company held on February 02, 2017. (opens in a new tab)
- 2 Feb · Results
  Financial results for the period ended December 31, 2016. (opens in a new tab)
Jan 2017
- 23 Jan · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2016. (opens in a new tab)
- 19 Jan · Updates
  Granting of authority to Pfizer Limited for certain rights in relation to identified injectable antibiotic products through a delegation of authority (opens in a new tab)
Dec 2016
- 5 Dec · Board meeting
  Meeting of the meeting of the Board of Directors of the Company held on December 02, 2016. (opens in a new tab)
- 1 Dec · Updates
  Termination of distribution arrangements for Meronem in India by AstraZeneca UK Limited - Extension of date of withdrawal. (opens in a new tab)
Nov 2016
- 29 Nov · Updates
  Contact details of Key Managerial Personnel authorised jointly and/or severally to determine and disseminate the materiality of an event and / or information to the Stock Exchange(s) (opens in a new tab)
- 15 Nov · Change in Company Secretary/Compliance Officer
  This has reference to letter dated November 11, 2016 informing about the resignation of Mr. Anantha Murthy N, Legal Counsel & Company Secretary and Compliance Officer of the Company with effect from closing hours of November 15, 2016. Further that Mr. Rajesh Marwaha, Chief Financial Officer of the Company will act as the Compliance Officer with effect from November 16, 2016. The recruitment process of Company Secretary and Compliance Officer by the Company is in progress. (opens in a new tab)
- 11 Nov · Management
  Mr. Anantha Murthy N, has resigned as the Legal Counsel & Company Secretary of Company. The Company has accepted his resignation and that he will be relieved from the services of the Company, from the closing hours of November 15, 2016. Consequently, he will cease to be the Compliance Officer of the Company, effective the closing hours of November 15, 2016. (opens in a new tab)
- 11 Nov · Results
  Financial results for the period ended September 30, 2016. (opens in a new tab)
Oct 2016
- 12 Oct · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2016. (opens in a new tab)
- 4 Oct · Legal
  Exchange had sought clarification from the Company with respect to recent news item captioned Embassy buys 10 acre land in Bengaluru for Rs. 255 cr .In this regard, the response from the Company is enclosed. (opens in a new tab)
- 4 Oct · Legal
  Exchange has sought clarification from the Company with respect to recent news item captioned Embassy buys 10 acre land in Bengaluru for Rs. 255 cr .In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Aug 2016
- 24 Aug · Updates
  Termination of distribution arrangements for Meronem in India by AstraZeneca UK Limited. (opens in a new tab)
- 12 Aug · Meeting
  Proceedings of the Annual General Meeting of the Company held on August 11 , 2016. (opens in a new tab)
- 12 Aug · Regulation 44(3) of SEBI (LODR), Reg., 2015
  Voting results of Annual General Meeting of the Company held on August 11, 2016, along with a copy of Scrutinizer's Report. (opens in a new tab)
- 9 Aug · Results
  Standalone financial results along with the Limited Review Report for the period ended June 30, 2016. (opens in a new tab)
Jul 2016
- 15 Jul · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. Company would also like to inform that the Trading Window shall remain closed for all Designated Persons, from June 16, 2016 to August 11, 2016 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. (opens in a new tab)
Jun 2016
- 16 Jun · Statement on Impact of Audit Qualifications
  Disclosure of the Impact of Audit Qualifications by the Listed Entities under Regulation 33 of SEBI(LODR) , Amendment Regulations, 2016. (opens in a new tab)
- 13 Jun · Meeting
  Share transfer Books and Register of Members of the Company will remain closed from August 4, 2016 to August 11, 2016(both days inclusive)for the purpose of Annual General Meeting of the Company is scheduled to be held on August 11, 2016. (opens in a new tab)
May 2016
- 25 May · Results
  Standalone financial results along with the Auditors Report for the period ended March 31, 2016. (opens in a new tab)
Apr 2016
- 26 Apr · Board meeting
  Inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2016. (opens in a new tab)
- 13 Apr · Disclosure
  Vide letter dated April 04, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. (opens in a new tab)
Mar 2016
- 23 Mar · Business
  Press release dated March 23, 2016 titled "Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes". (opens in a new tab)
Feb 2016
- 6 Feb · Board meeting
  At the Board Meeting of the Company held on Saturday ; February 6, 2016, the Board of Directors considered, inter- alia the following: 1) The Board noted the resignation of Mr. Justin Ooi as Director of the Company, effective January 11, 2016.2) The Board of Directors approved the re-appointment of Mr. Sanjay Murdeshwar as Managing Director of the Company for a period of 3 years, to be effective from May 02, 2016. (opens in a new tab)
- 6 Feb · Results
  Standalone financial results along with the Limited Review Report for the period ended December 31, 2015. (opens in a new tab)
Jan 2016
- 14 Jan · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2015. (opens in a new tab)
- 12 Jan · Management
  Mr. Justin Ooi, has resigned as Director of the Company effective from the close of business hours on January 11, 2016. (opens in a new tab)
Dec 2015
- 4 Dec · Updates
  That as required under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board at its meeting held on December 2, 2015, authorized the following Key Managerial Personnel, jointly and/or severally to determine and disseminate the materiality of an event and / or information to the Stock Exchanges: a) Mr. Sanjay Murdeshwar, Managing Director b) Mr. Anantha Murthy N, Company Secretar c) Mr. Rajesh Marwaha, Chief Financial Officer. (opens in a new tab)
- 3 Dec · Board meeting
  Outcome of Board Meeting held on December 02, 2015. (opens in a new tab)
Nov 2015
- 6 Nov · Board meeting
  Board Meeting of the Company held on November 6, 2015, the Board of Directors considered inter-alia the following:1. The Board accepted the resignation of Ms. Rebekah Martin as Director of the Company, effective November 6, 2015.2. The Board appointed Ms. Claire-Marie o' Grady as Director of the Company in the vacancy caused by the resignation of Ms. Rebekah Marti with immediate effect. (opens in a new tab)
- 6 Nov · Results
  Standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015. (opens in a new tab)
Oct 2015
- 14 Oct · Board meeting
  Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2015. (opens in a new tab)
Sep 2015
- 15 Sep · Updates
  Update on Appeal filed before Securities Appellate Tribunal - Mumbai, regarding delisting matter. (opens in a new tab)

AstraZeneca Pharma India share news and announcements

Jul 2017

Jun 2017

May 2017

Apr 2017

Feb 2017

Jan 2017

Dec 2016

Nov 2016

Oct 2016

Aug 2016

Jul 2016

Jun 2016

May 2016

Apr 2016

Mar 2016

Feb 2016

Jan 2016

Dec 2015

Nov 2015

Oct 2015

Sep 2015